Opthea Limited (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea Limited (ASX: OPT)
Latest News
Share Market News
Opthea share price rockets higher on bullish broker report
Speculative
3 exciting small cap ASX shares to buy in September
Share Fallers
Why Bendigo and Adelaide Bank, Genworth Mortgage Insurance, Opthea, & Orocobre dropped lower
Share Gainers
Why iSignthis and Opthea shares are up over 400% in 2019
Share Fallers
Why Crown Resorts, Mirvac, Opthea, & Northern Star shares dropped lower today
52-Week Highs
Why Newcrest and these ASX shares are flying high right now
Share Market News
Here's why the Opthea share price is up 130% today
Share Gainers
Why Althea, Northern Star, Opthea, & Suncorp shares raced higher today
Share Gainers
Why the Opthea share price could zoom higher today
⏸️ Investing
5 ASX shares to build a portfolio around
Share Gainers
These small cap ASX shares have pushed higher on Wednesday
Healthcare Shares
Can Opthea Ltd (ASX:OPT) be the next Cochlear Limited (ASX:COH)?
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea Limited
Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage.
